Overview

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Status:
Terminated

Trial end date:
2021-02-03

Target enrollment:

Participant gender:

Summary

This is a study to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Transgene

Treatments:

Antibodies
Antibodies, Blocking
Antibodies, Monoclonal
Nivolumab